Infliximab biosimilar gets PBS listing

From the 1st December the infliximab biosimilar Inflectra™ will be listed on the PBS for the same indications that apply to its comparator drug Remicade™. The PBS update shows that Inflectra™ and its originator biologic is marked as equivalent on the Schedule of Pharmaceutical Benefits (‘a’ flagged), for the purposes of substitution by a pharmacist ...

Already a member?

Login to keep reading.

© 2021 the limbic